Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 6/20 | 0.44 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.42 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630034 | 0.92 | KCNQ1 (0.56) | KMT2AKCNQ1POLBHCRTR1HCRTR2 | |
| SCHEMBL1380661 | 0.92 | KCNQ1 (0.56) | KMT2AKCNQ1POLBHCRTR1HCRTR2 | |
| SCHEMBL631193 | 0.90 | MEN1 (0.47) | MEN1KMT2AKCNQ1POLBFKBP1A | |
| SCHEMBL629996 | 0.88 | KCNQ1 (0.48) | KCNQ1POLBHCRTR1HCRTR2BDKRB1 | |
| SCHEMBL1383354 | 0.88 | KCNQ1 (0.48) | KCNQ1POLBHCRTR1HCRTR2BDKRB1 | |
| SCHEMBL8268291 | 0.85 | KCNQ1 (0.52) | KCNQ1POLBHCRTR1HCRTR2BDKRB1 | |
| SCHEMBL1382694 | 0.85 | KCNQ1 (0.52) | KCNQ1POLBHCRTR1HCRTR2BDKRB1 | |
| SCHEMBL630185 | 0.85 | KCNQ1 (0.52) | KCNQ1POLBHCRTR1HCRTR2BDKRB1 | |
| SCHEMBL630124 | 0.84 | POLB (0.51) | MEN1KMT2AKCNQ1POLBHCRTR1 | |
| SCHEMBL1382042 | 0.83 | KCNQ1 (0.54) | KMT2AKCNQ1FKBP1AHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | claimed |
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | MEN1 4809/4885KMT2A 4807/4885KCNQ1 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.